Roche announced it will acquire PathAI in a deal valued at $750 million upfront, aiming to expand AI-powered digital pathology capabilities for pathology labs and biopharma development. PathAI’s technology focuses on applying machine learning to pathology workflows to help standardize analyses and speed decisions. The acquisition underscores how large platforms are consolidating around digital pathology as a data layer for drug development, clinical trials, and biomarker efforts. Roche’s move positions it to integrate PathAI’s tools more tightly across its diagnostics and pharmaceutical R&D operations, while strengthening its ability to serve partners building AI-enabled translational programs.